Cytokine regulation of natural killer cell effector functions

BioFactors

Volumn 36, Issue 4, 2010, Pages 274-288

  Zwirner, Norberto W ^a,b   Domaica, Carolina I ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cytokines; Immunity; NK cells

Indexed keywords

ALPHA INTERFERON; CD16 ANTIGEN; CELL SURFACE RECEPTOR; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 27; JANUS KINASE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL ACTIVATION; CELL FUNCTION; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; TARGET CELL;

ANIMALS; CYTOKINES; HUMANS; INTERLEUKIN-12; INTERLEUKIN-15; INTERLEUKIN-18; INTERLEUKIN-2; INTERLEUKINS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78149479990     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.107     Document Type: Article

References (200)

1. Ikeda, H., Old, L. J., and Schreiber, R. D. (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13, 95-109.
2. Balkwill, F. (2002) Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 13, 135-141.
3. Ferlazzo, G., Pack, M., Thomas, D., Paludan, C., Schmid, D., Strowig, T., Bougras, G., Muller, W. A., Moretta, L., and Munz, C. (2004) Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. USA 101, 16606-16611.
4. Martin-Fontecha, A., Thomsen, L. L., Brett, S., Gerard, C., Lipp, M., Lanzavecchia, A., and Sallusto, F. (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 5, 1260-1265.
5. Strowig, T., Brilot, F., and Munz, C. (2008) Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J. Immunol. 180, 7785-7791.
6. Caligiuri, M. A. (2008) Human natural killer cells. Blood 112, 461-469.
7. dim NK cells upon activation. J. Immunol. 178, 4947-4955.
8. dim cells: role of contact with peripheral fibroblasts. J. Immunol. 179, 89-94.
9. + NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J. Immunol. 166, 6477-6482.
10. high NK cells to lymph nodes primed by dendritic cells. J. Immunol. 181, 5323-5330.
11. Hayakawa, Y., and Smyth, M. J. (2006) CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176, 1517-1524.
12. Lanier, L. L. (2005) NK cell recognition. Annu. Rev. Immunol. 23, 225-274.
13. Moretta, L., Bottino, C., Pende, D., Castriconi, R., Mingari, M. C., and Moretta, A. (2006) Surface NK receptors and their ligands on tumor cells. Semin. Immunol. 18, 151-158.
14. Meyaard, L., Adema, G. J., Chang, C., Woollatt, E., Sutherland, G. R., Lanier, L. L., and Phillips, J. H. (1997) LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity 7, 283-290.
15. Schatzle, J. D., Sheu, S., Stepp, S. E., Mathew, P. A., Bennett, M., and Kumar, V. (1999) Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proc. Natl. Acad. Sci. USA 96, 3870-3875.
16. Vaidya, S. V. and Mathew, P. A. (2006) Of mice and men: different functions of the murine and human 2B4 (CD244) receptor on NK cells. Immunol. Lett. 105, 180-184.
17. Messmer, B., Eissmann, P., Stark, S., and Watzl, C. (2006) CD48 stimulation by 2B4 (CD244)-expressing targets activates human NK cells. J. Immunol. 176, 4646-4650.
18. Chlewicki, L. K., Velikovsky, C. A., Balakrishnan, V., Mariuzza, R. A., and Kumar, V. (2008) Molecular basis of the dual functions of 2B4 (CD244). J. Immunol. 180, 8159-8167.
19. Lebbink, R. J., de Ruiter, T., Adelmeijer, J., Brenkman, A. B., van Helvoort, J. M., Koch, M., Farndale, R. W., Lisman, T., Sonnenberg, A., Lenting, P. J., and Meyaard, L. (2006) Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J. Exp. Med. 203, 1419-1425.
20. Favier, B., Lemaoult, J., Lesport, E., and Carosella, E. D. (2010) ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J. 24, 689-699.
21. Lesport, E., Baudhuin, J., LeMaoult, J., Sousa, S., Doliger, C., Carosella, E. D., and Favier, B. (2009) Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell. Hum. Immunol. 70, 1000-1005.
22. Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y. J., Yang, L., French, A. R., Sunwoo, J. B., Lemieux, S., Hansen, T. H., and Yokoyama, W. M. (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436, 709-713.
23. Kim, S., Sunwoo, J. B., Yang, L., Choi, T., Song, Y. J., French, A. R., Vlahiotis, A., Piccirillo, J. F., Cella, M., Colonna, M., Mohanakumar, T., Hsu, K. C., Dupont, B., and Yokoyama, W. M. (2008) HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc. Natl. Acad. Sci. USA 105, 3053-3058.
24. Brandt, C. S., Baratin, M., Yi, E. C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C. D., Kaifu, T., Chabannon, C., Moretta, A., West, R., Xu, W., Vivier, E., and Levin, S. D. (2009) The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 206, 1495-1503.
25. Pogge von Strandmann, E., Simhadri, V. R., von Tresckow, B., Sasse, S., Reiners, K. S., Hansen, H. P., Rothe, A., Boll, B., Simhadri, V. L., Borchmann, P., McKinnon, P. J., Hallek, M., and Engert, A. (2007) Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27, 965-974.
26. Simhadri, V. R., Reiners, K. S., Hansen, H. P., Topolar, D., Simhadri, V. L., Nohroudi, K., Kufer, T. A., Engert, A., and Pogge von Strandmann, E. (2008) Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One 3, e3377.
27. Eagle, R. A. and Trowsdale, J. (2007) Promiscuity and the single receptor: NKG2D. Nat. Rev. Immunol. 7, 737-744.
28. Eagle, R. A., Traherne, J. A., Hair, J. R., and Jafferji, I., Trowsdale, J. (2009) ULBP6/RAET1L is an additional human NKG2D ligand. Eur. J. Immunol. 39, 3207-3216.
29. Zwirner, N. W., Fuertes, M. B., Girart, M. V., Domaica, C. I., and Rossi, L. E. (2007) Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev. 18, 159-170.
30. Gasser, S., Orsulic, S., Brown, E. J., and Raulet, D. H. (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436, 1186-1190.
31. Groh, V., Wu, J., Yee, C., and Spies, T. (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738.
32. Salih, H. R., Rammensee, H.-G., and Steinle, A. (2002) Down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 169, 4098-4102.
33. Fuertes, M. B., Girart, M. V., Molinero, L. L., Domaica, C. I., Rossi, L. E., Barrio, M. M., Mordoh, J., Rabinovich, G. A., and Zwirner, N. W. (2008) Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J. Immunol. 180, 4606-4614.
34. Pende, D., Spaggiari, G. M., Marcenaro, S., Martini, S., Rivera, P., Capobianco, A., Falco, M., Lanino, E., Pierri, I., Zambello, R., Bacigalupo, A., Mingari, M. C., Moretta, A., and Moretta, L. (2005) Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105, 2066-2073.
35. Castriconi, R., Dondero, A., Corrias, M. V., Lanino, E., Pende, D., Moretta, L., Bottino, C., and Moretta, A. (2004) Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 64, 9180-9184.
36. El-Sherbiny, Y. M., Meade, J. L., Holmes, T. D., McGonagle, D., Mackie, S. L., Morgan, A. W., Cook, G., Feyler, S., Richards, S. J., Davies, F. E., Morgan, G. J., and Cook, G. P. (2007) The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 67, 8444-8449.
37. Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., Pende, D., Groh, V., Biassoni, R., Hoglund, P., Kato, M., Shibuya, K., Schadendorf, D., Anichini, A., Ferrone, S., Velardi, A., Karre, K., Shibuya, A., Carbone, E., and Colucci, F. (2009) NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119, 1251-1263.
38. Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita, H., Gilfillan, S., Colonna, M., and Smyth, M. J. (2010) DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J. Immunol. 184, 902-911.
39. Iguchi-Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara-Hanaoka, S., Honda, S., Yasui, T., Kikutani, H., Shibuya, K., and Shibuya, A. (2008) Accelerated tumor growth in mice deficient in DNAM-1 receptor. J. Exp. Med. 205, 2959-2964.
40. Carlsten, M., Norell, H., Bryceson, Y. T., Poschke, I., Schedvins, K., Ljunggren, H. G., Kiessling, R., and Malmberg, K. J. (2009) Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J. Immunol. 183, 4921-4930.
41. Voskoboinik, I., Smyth, M. J., and Trapani, J. A. (2006) Perforin-mediated target-cell death and immune homeostasis. Nat. Rev. Immunol. 6, 940-952.
42. Baetu, T. M. and Hiscott, J. (2002) On the TRAIL to apoptosis. Cytokine Growth Factor Rev. 13, 199-207.
43. Tomescu, C., Chehimi, J., Maino, V. C., and Montaner, L. J. (2009) Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN-alpha by human NK cells after CD107a degranulation. J. Leukoc. Biol. 85, 871-876.
44. Becknell, B. and Caligiuri, M. A. (2005) Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv. Immunol. 86, 209-239.
45. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., Seipp, C. A., Simpson, C., and Reichert, C. M. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492.
46. Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., Orchard, P. J., Blazar, B. R., Wagner, J. E., Slungaard, A., Weisdorf, D. J., Okazaki, I. J., and McGlave, P. B. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105, 3051-3057.
47. Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., and Zitvogel, L. (2008) Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat. Immunol. 9, 486-494.
48. Ma, A., Koka, R., and Burkett, P. (2006) Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu. Rev. Immunol. 24, 657-679.
49. Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., Paradise, C., Kunkel, L., and Rosenberg, S. A. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116.
50. de Castro, F. A., Palma, P. V., Morais, F. R., Simoes, B. P., Carvalho, P. V., Ismael, S. J., Lima, C. P., and Voltarelli, J. C. (2003) Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk. Lymphoma 44, 2061-2067.
51. Robertson, M. J., Cameron, C., Atkins, M. B., Gordon, M. S., Lotze, M. T., Sherman, M. L., and Ritz, J. (1999) Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res. 5, 9-16.
52. Robertson, M. J., Mier, J. W., Logan, T., Atkins, M., Koon, H., Koch, K. M., Kathman, S., Pandite, L. N., Oei, C., Kirby, L. C., Jewell, R. C., Bell, W. N., Thurmond, L. M., Weisenbach, J., Roberts, S., and Dar, M. M. (2006) Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. 12, 4265-4273.
53. Davis, I. D., Skrumsager, B. K., Cebon, J., Nicholaou, T., Barlow, J. W., Moller, N. P., Skak, K., Lundsgaard, D., Frederiksen, K. S., Thygesen, P., and McArthur, G. A. (2007) An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 13, 3630-3636.
54. Suzuki, H., Duncan, G. S., Takimoto, H., and Mak, T. W. (1997) Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J. Exp. Med. 185, 499-505.
55. + cell development. J. Immunol. 159, 5931-5935.
56. DiSanto, J. P., Muller, W., Guy-Grand, D., Fischer, A., and Rajewsky, K. (1995) Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc. Natl. Acad. Sci. USA 92, 377-381.
57. Cao, X., Shores, E. W., Hu-Li, J., Anver, M. R., Kelsall, B. L., Russell, S. M., Drago, J., Noguchi, M., Grinberg, A., Bloom, E. T., Paul, W. E., Katz, S. I., Love, P. E., and Leonard, W. J. (1995) Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 2, 223-238.
58. Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., Brasel, K., Morrissey, P. J., Stocking, K., Schuh, J. C., Joyce, S., and Peschon, J. J. (2000) Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771-780.
59. Lodolce, J. P., Boone, D. L., Chai, S., Swain, R. E., Dassopoulos, T., Trettin, S., and Ma, A. (1998) IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669-676.
60. + T cells. J. Exp. Med. 193, 219-231.
61. Koka, R., Burkett, P. R., Chien, M., Chai, S., Chan, F., Lodolce, J. P., Boone, D. L., and Ma, A. (2003) Interleukin (IL)-15Rα-deficient natural killer cells survive in normal but not IL-15Rα-deficient mice. J. Exp. Med. 197, 977-984.
62. Saleh, A., Davies, G. E., Pascal, V., Wright, P. W., Hodge, D. L., Cho, E. H., Lockett, S. J., Abshari, M., and Anderson, S. K. (2004) Identification of probabilistic transcriptional switches in the Ly49 gene cluster: a eukaryotic mechanism for selective gene activation. Immunity 21, 55-66.
63. Colucci, F., Caligiuri, M. A., and Di Santo, J. P. (2003) What does it take to make a natural killer? Nat. Rev. Immunol. 3, 413-425.
64. Kasaian, M. T., Whitters, M. J., Carter, L. L., Lowe, L. D., Jussif, J. M., Deng, B., Johnson, K. A., Witek, J. S., Senices, M., Konz, R. F., Wurster, A. L., Donaldson, D. D., Collins, M., Young, D. A., and Grusby, M. J. (2002) IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16, 559-569.
65. + cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur. J. Immunol. 33, 3439-3447.
66. + T cells in vivo. Blood 111, 5008-5016.
67. Granucci, F., Vizzardelli, C., Pavelka, N., Feau, S., Persico, M., Virzi, E., Rescigno, M., Moro, G., and Ricciardi-Castagnoli, P. (2001) Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. 2, 882-888.
68. Miyazaki, T., Kawahara, A., Fujii, H., Nakagawa, Y., Minami, Y., Liu, Z. J., Oishi, I., Silvennoinen, O., Witthuhn, B. A., Ihle, J. N., Taniguchi, T. (1994) Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 266, 1045-1047.
69. Shimoda, K., Tsutsui, H., Aoki, K., Kato, K., Matsuda, T., Numata, A., Takase, K., Yamamoto, T., Nukina, H., Hoshino, T., Asano, Y., Gondo, H., Okamura, T., Okamura, S., Nakayama, K., Nakanishi, K., Niho, Y., and Harada, M. (2002) Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood 99, 2094-2099.
70. Yu, C. R., Young, H. A., and Ortaldo, J. R. (1998) Characterization of cytokine differential induction of STAT complexes in primary human T and NK cells. J. Leukoc. Biol. 64, 245-258.
71. Strengell, M., Matikainen, S., Siren, J., Lehtonen, A., Foster, D., Julkunen, I., and Sareneva, T. (2003) IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J. Immunol. 170, 5464-5469.
72. Zeng, R., Spolski, R., Casas, E., Zhu, W., Levy, D. E., and Leonard, W. J. (2007) The molecular basis of IL-21-mediated proliferation. Blood 109, 4135-4142.
73. Parham, C., Chirica, M., Timans, J., Vaisberg, E., Travis, M., Cheung, J., Pflanz, S., Zhang, R., Singh, K. P., Vega, F., To, W., Wagner, J., O'Farrell, A. M., McClanahan, T., Zurawski, S., Hannum, C., Gorman, D., Rennick, D. M., Kastelein, R. A., de Waal Malefyt, R., and Moore, K. W. (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168, 5699-5708.
74. O'Shea, J. J., Gadina, M., and Schreiber, R. D. (2002) Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109, S121-S131.
75. Nguyen, K. B., Salazar-Mather, T. P., Dalod, M. Y., Van Deusen, J. B., Wei, X. Q., Liew, F. Y., Caligiuri, M. A., Durbin, J. E., and Biron, C. A. (2002) Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 169, 4279-4287.
76. Fehniger, T. A., Bluman, E. M., Porter, M. M., Mrozek, E., Cooper, M. A., VanDeusen, J. B., Frankel, S. R., Stock, W., and Caligiuri, M. A. (2000) Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J. Clin. Invest. 106, 117-124.
77. Biron, C. A., Young, H. A., and Kasaian, M. T. (1990) Interleukin 2-induced proliferation of murine natural killer cells in vivo. J. Exp. Med. 171, 173-188.
78. Lotzova, E., Savary, C. A., and Herberman, R. B. (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J. Immunol. 138, 2718-2727.
79. Wang, K. S., Frank, D. A., and Ritz, J. (2000) Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood 95, 3183-3190.
80. Lucas, M., Schachterle, W., Oberle, K., Aichele, P., and Diefenbach, A. (2007) Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26, 503-517.
81. Brilot, F., Strowig, T., Roberts, S. M., Arrey, F., and Munz, C. (2007) NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Ralpha. J. Clin. Invest. 117, 3316-3329.
82. Huntington, N. D., Puthalakath, H., Gunn, P., Naik, E., Michalak, E. M., Smyth, M. J., Tabarias, H., Degli-Esposti, M. A., Dewson, G., Willis, S. N., Motoyama, N., Huang, D. C., Nutt, S. L., Tarlinton, D. M., and Strasser, A. (2007) Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nat. Immunol. 8, 856-863.
83. Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., and Caligiuri, M. A. (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395-1403.
84. Huntington, N. D., Legrand, N., Alves, N. L., Jaron, B., Weijer, K., Plet, A., Corcuff, E., Mortier, E., Jacques, Y., Spits, H., and Di Santo, J. P. (2009) IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J. Exp. Med. 206, 25-34.
85. Kobayashi, H., Dubois, S., Sato, N., Sabzevari, H., Sakai, Y., Waldmann, T. A., and Tagaya, Y. (2005) Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105, 721-727.
86. Cooper, M. A., Bush, J. E., Fehniger, T. A., VanDeusen, J. B., Waite, R. E., Liu, Y., Aguila, H. L., and Caligiuri, M. A. (2002) In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100, 3633-3638.
87. Koka, R., Burkett, P., Chien, M., Chai, S., Boone, D. L., and Ma, A. (2004) Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J. Immunol. 173, 3594-3598.
88. + T cell homeostasis. J. Exp. Med. 200, 825-834.
89. Mattei, F., Schiavoni, G., Belardelli, F., and Tough, D. F. (2001) IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J. Immunol. 167, 1179-1187.
90. Carson, W. E., Fehniger, T. A., Haldar, S., Eckhert, K., Lindemann, M. J., Lai, C. F., Croce, C. M., Baumann, H., and Caligiuri, M. A. (1997) A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 99, 937-943.
91. dim) human NK cells. J. Immunol. 156, 3254-3259.
92. Ferlazzo, G., Thomas, D., Lin, S. L., Goodman, K., Morandi, B., Muller, W. A., Moretta, A., and Munz, C. (2004) The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 172, 1455-1462.
93. Zhang, J., Scordi, I., Smyth, M. J., and Lichtenheld, M. G. (1999) Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J. Exp. Med. 190, 1297-1308.
94. Girart, M. V., Fuertes, M. B., Domaica, C. I., Rossi, L. E., and Zwirner, N. W. (2007) Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J. Immunol. 179, 3472-3479.
95. Skak, K., Frederiksen, K. S., and Lundsgaard, D. (2008) Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology 123, 575-583.
96. Pillet, A. H., Bugault, F., Theze, J., Chakrabarti, L. A., and Rose, T. (2009) A programmed switch from IL-15- to IL-2-dependent activation in human NK cells. J. Immunol. 182, 6267-6277.
97. Watford, W. T., Moriguchi, M., Morinobu, A., and O'shea, J. J. (2003) The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 14, 361-368.
98. Mailliard, R. B., Son, Y. I., Redlinger, R., Coates, P. T., Giermasz, A., Morel, P. A., Storkus, W. J., and Kalinski, P. (2003) Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J. Immunol. 171, 2366-2373.
99. + cells in response to IL-12, IL-18, or the combination of IL-12 and IL-18. Cell Immunol. 212, 71-81.
100. +high stage and effector functions. J. Immunol. 172, 88-96.
101. Kamath, A. T., Sheasby, C. E., and Tough, D. F. (2005) Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. J. Immunol. 174, 767-776.
102. Andoniou, C. E., van Dommelen, S. L., Voigt, V., Andrews, D. M., Brizard, G., Asselin-Paturel, C., Delale, T., Stacey, K. J., Trinchieri, G., and Degli-Esposti, M. A. (2005) Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat. Immunol. 6, 1011-1019.
103. Lauwerys, B. R., Renauld, J. C., and Houssiau, F. A. (1999) Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine 11, 822-830.
104. Sotiriadou, N. N., Perez, S. A., Gritzapis, A. D., Mahaira, L. G., Salagianni, M., Baxevanis, C. N., and Papamichail, M. (2005) Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and function. Cell Immunol. 234, 67-75.
105. Fehniger, T. A., Shah, M. H., Turner, M. J., VanDeusen, J. B., Whitman, S. P., Cooper, M. A., Suzuki, K., Wechser, M., Goodsaid, F., and Caligiuri, M. A. (1999) Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. 162, 4511-4520.
106. Tripp, C. S., Wolf, S. F., and Unanue, E. R. (1993) Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc. Natl. Acad. Sci. USA 90, 3725-3729.
107. Hashimoto, W., Osaki, T., Okamura, H., Robbins, P. D., Kurimoto, M., Nagata, S., Lotze, M. T., and Tahara, H. (1999) Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J. Immunol. 163, 583-589.
108. Kodama, T., Takeda, K., Shimozato, O., Hayakawa, Y., Atsuta, M., Kobayashi, K., Ito, M., Yagita, H., and Okumura, K. (1999) Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur. J. Immunol. 29, 1390-1396.
109. Orange, J. S., Wang, B., Terhorst, C., and Biron, C. A. (1995) Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J. Exp. Med. 182, 1045-1056.
110. Yao, L., Sgadari, C., Furuke, K., Bloom, E. T., Teruya-Feldstein, J., and Tosato, G. (1999) Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93, 1612-1621.
111. + NK helper cells. J. Exp. Med. 202, 941-953.
112. Liu, B., Mori, I., Hossain, M. J., Dong, L., Takeda, K., and Kimura, Y. (2004) Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. J. Gen. Virol. 85, 423-428.
113. Hyodo, Y., Matsui, K., Hayashi, N., Tsutsui, H., Kashiwamura, S., Yamauchi, H., Hiroishi, K., Takeda, K., Tagawa, Y., Iwakura, Y., Kayagaki, N., Kurimoto, M., Okamura, H., Hada, T., Yagita, H., Akira, S., Nakanishi, K., and Higashino, K. (1999) IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J. Immunol. 162, 1662-1668.
114. Son, Y. I., Dallal, R. M., Mailliard, R. B., Egawa, S., Jonak, Z. L., and Lotze, M. T. (2001) Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res. 61, 884-888.
115. Chaix, J., Tessmer, M. S., Hoebe, K., Fuseri, N., Ryffel, B., Dalod, M., Alexopoulou, L., Beutler, B., Brossay, L., Vivier, E., and Walzer, T. (2008) Cutting edge: priming of NK cells by IL-18. J. Immunol. 181, 1627-1631.
116. Reading, P. C., Whitney, P. G., Barr, D. P., Wojtasiak, M., Mintern, J. D., Waithman, J., and Brooks, A. G. (2007) IL-18, but not IL-12, regulates NK cell activity following intranasal herpes simplex virus type 1 infection. J. Immunol. 179, 3214-3221.
117. Semino, C., Angelini, G., Poggi, A., and Rubartelli, A. (2005) NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106, 609-616.
118. Hodge, D. L., Subleski, J. J., Reynolds, D. A., Buschman, M. D., Schill, W. B., Burkett, M. W., Malyguine, A. M., and Young, H. A. (2006) The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death. J. Interferon Cytokine Res. 26, 706-718.
119. Spolski, R. and Leonard, W. J. (2008) Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26, 57-79.
120. Nutt, S. L., Brady, J., Hayakawa, Y., and Smyth, M. J. (2004) Interleukin 21: a key player in lymphocyte maturation. Crit. Rev. Immunol. 24, 239-250.
121. Brady, J., Hayakawa, Y., Smyth, M. J., and Nutt, S. L. (2004) IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172, 2048-2058.
122. Takaki, R., Hayakawa, Y., Nelson, A., Sivakumar, P. V., Hughes, S., Smyth, M. J., and Lanier, L. L. (2005) IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J. Immunol. 175, 2167-2173.
123. Ugai, S., Shimozato, O., Yu, L., Wang, Y. Q., Kawamura, K., Yamamoto, H., Yamaguchi, T., Saisho, H., Sakiyama, S., and Tagawa, M. (2003) Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther. 10, 771-778.
124. Wendt, K., Wilk, E., Buyny, S., Schmidt, R. E., and Jacobs, R. (2007) Interleukin-21 differentially affects human natural killer cell subsets. Immunology 122, 486-495.
125. Gays, F., Martin, K., Kenefeck, R., Aust, J. G., and Brooks, C. G. (2005) Multiple cytokines regulate the NK gene complex-encoded receptor repertoire of mature NK cells and T cells. J. Immunol. 175, 2938-2947.
126. + T cells. J. Immunol. 176, 1490-1497.
127. Kastelein, R. A., Hunter, C. A., and Cua, D. J. (2007) Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25, 221-242.
128. Hu, J., Yuan, X., Belladonna, M. L., Ong, J. M., Wachsmann-Hogiu, S., Farkas, D. L., Black, K. L., and Yu, J. S. (2006) Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 66, 8887-8896.
129. Kaiga, T., Sato, M., Kaneda, H., Iwakura, Y., Takayama, T., and Tahara, H. (2007) Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J. Immunol. 178, 7571-7580.
130. Hu, P., Hu, H. D., Chen, M., Peng, M. L., Tang, L., Tang, K. F., Matsui, M., Belladonna, M. L., Yoshimoto, T., Zhang, D. Z., Xiang, R., and Ren, H. (2009) Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol. Immunol. 46, 1654-1662.
131. Lo, C. H., Lee, S. C., Wu, P. Y., Pan, W. Y., Su, J., Cheng, C. W., Roffler, S. R., Chiang, B. L., Lee, C. N., Wu, C. W., and Tao, M. H. (2003) Antitumor and antimetastatic activity of IL-23. J. Immunol. 171, 600-607.
132. Oniki, S., Nagai, H., Horikawa, T., Furukawa, J., Belladonna, M. L., Yoshimoto, T., Hara, I., and Nishigori, C. (2006) Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 66, 6395-6404.
133. Chiyo, M., Shimozato, O., Yu, L., Kawamura, K., Iizasa, T., Fujisawa, T., and Tagawa, M. (2005) Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer. 115, 437-442.
134. + T cells. J. Immunol. 173, 7170-7182.
135. Dibra, D., Cutrera, J. J., Xia, X., Birkenbach, M. P., and Li, S. (2009) Expression of WSX1 in tumors sensitizes IL-27 signaling-independent natural killer cell surveillance. Cancer Res. 69, 5505-5513.
136. Biron, C. A., Sonnenfeld, G., and Welsh, R. M. (1984) Interferon induces natural killer cell blastogenesis in vivo. J. Leukoc. Biol. 35, 31-37.
137. Sato, K., Hida, S., Takayanagi, H., Yokochi, T., Kayagaki, N., Takeda, K., Yagita, H., Okumura, K., Tanaka, N., Taniguchi, T., and Ogasawara, K. (2001) Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur. J. Immunol. 31, 3138-3146.
138. Orange, J. S. and Biron, C. A. (1996) Characterization of early IL-12, IFN-alphabeta, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J. Immunol. 156, 4746-4756.
139. Gerosa, F., Gobbi, A., Zorzi, P., Burg, S., Briere, F., Carra, G., and Trinchieri, G. (2005) The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J. Immunol. 174, 727-734.
140. Liang, S., Wei, H., Sun, R., and Tian, Z. (2003) IFNalpha regulates NK cell cytotoxicity through STAT1 pathway. Cytokine 23, 190-199.
141. Swann, J. B., Hayakawa, Y., Zerafa, N., Sheehan, K. C., Scott, B., Schreiber, R. D., Hertzog, P., and Smyth, M. J. (2007) Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178, 7540-7549.
142. Nguyen, K. B., Cousens, L. P., Doughty, L. A., Pien, G. C., Durbin, J. E., and Biron, C. A. (2000) Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat. Immunol. 1, 70-76.
143. Malejczyk, J., Malejczyk, M., Urbanski, A., Kock, A., Jablonska, S., Orth, G., and Luger, T. A. (1991) Constitutive release of IL6 by human papillomavirus type 16 (HPV16)-harboring keratinocytes: a mechanism augmenting the NK-cell-mediated lysis of HPV-bearing neoplastic cells. Cell Immunol. 136, 155-164.
144. Passos, S. T., Silver, J. S., O'Hara, A. C., Sehy, D., Stumhofer, J. S., and Hunter, C. A. (2010) IL-6 promotes NK cell production of IL-17 during toxoplasmosis. J. Immunol. 184, 1776-1783.
145. Armant, M., Delespesse, G., and Sarfati, M. (1995) IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. Immunology 85, 331-337.
146. Newman, K. C., and Riley, E. M. (2007) Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens. Nat. Rev. Immunol. 7, 279-291.
147. Crabe, S., Guay-Giroux, A., Tormo, A. J., Duluc, D., Lissilaa, R., Guilhot, F., Mavoungou-Bigouagou, U., Lefouili, F., Cognet, I., Ferlin, W., Elson, G., Jeannin, P., and Gauchat, J. F. (2009) The IL-27 p28 subunit binds cytokine-like factor 1 to form a cytokine regulating NK and T cell activities requiring IL-6R for signaling. J. Immunol. 183, 7692-7702.
148. Ross, M. E. and Caligiuri, M. A. (1997) Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 89, 910-918.
149. bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101, 3052-3057.
150. DeBlaker-Hohe, D. F., Yamauchi, A., Yu, C. R., Horvath-Arcidiacono, J. A., and Bloom, E. T. (1995) IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Immunol. 165, 33-43.
151. Carson, W. E., Dierksheide, J. E., Jabbour, S., Anghelina, M., Bouchard, P., Ku, G., Yu, H., Baumann, H., Shah, M. H., Cooper, M. A., Durbin, J., and Caligiuri, M. A. (2000) Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood 96, 1465-1473.
152. Rodriguez-Galán, M. C., Reynolds, D., Correa, S. G., Iribarren, P., Watanabe, M., and Young, H. A. (2009) Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity. J. Immunol. 183, 740-748.
153. Smyth, M. J., Swann, J., Kelly, J. M., Cretney, E., Yokoyama, W. M., Diefenbach, A., Sayers, T. J., and Hayakawa, Y. (2004) NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J. Exp. Med. 200, 1325-1335.
154. Yu, J., Wei, M., Becknell, B., Trotta, R., Liu, S., Boyd, Z., Jaung, M. S., Blaser, B. W., Sun, J., Benson, D. M. Jr., Mao, H., Yokohama, A., Bhatt, D., Shen, L., Davuluri, R., Weinstein, M., Marcucci, G., and Caligiuri, M. A. (2006) Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity 24, 575-590.
155. Takeda, K., Tsutsui, H., Yoshimoto, T., Adachi, O., Yoshida, N., Kishimoto, T., Okamura, H., Nakanishi, K., and Akira, S. (1998) Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8, 383-390.
156. French, A. R., Holroyd, E. B., Yang, L., Kim, S., and Yokoyama, W. M. (2006) IL-18 acts synergistically with IL-15 in stimulating natural killer cell proliferation. Cytokine 35, 229-234.
157. Freudenberg, M. A., Merlin, T., Kalis, C., Chvatchko, Y., Stubig, H., and Galanos, C. (2002) A murine, IL-12-independent pathway of IFN-gamma induction by gram-negative bacteria based on STAT4 activation by Type I IFN and IL-18 signaling. J. Immunol. 169, 1665-1668.
158. de Rham, C., Ferrari-Lacraz, S., Jendly, S., Schneiter, G., Dayer, J. M., and Villard, J. (2007) The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res. Ther. 9, R125.
159. Ortaldo, J. R. and Young, H. A. (2003) Expression of IFN-gamma upon triggering of activating Ly49D NK receptors in vitro and in vivo: costimulation with IL-12 or IL-18 overrides inhibitory receptors. J. Immunol. 170, 1763-1769.
160. Lanier, L. L. (2008) Evolutionary struggles between NK cells and viruses. Nat. Rev. Immunol. 8, 259-268.
161. Tesniere, A., Panaretakis, T., Kepp, O., Apetoh, L., Ghiringhelli, F., Zitvogel, L., and Kroemer, G. (2008) Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15, 3-12.
162. Yokoyama, W. M. and Kim, S. (2006) Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol. Rev. 214, 143-154.
163. Brodin, P. and Hoglund, P. (2008) Beyond licensing and disarming: a quantitative view on NK-cell education. Eur. J. Immunol. 38, 2934-2937.
164. Orr, M. T., Murphy, W. J., and Lanier, L. L. (2010) 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nat. Immunol. 11, 321-327.
165. Peritt, D., Robertson, S., Gri, G., Showe, L., Aste-Amezaga, M., and Trinchieri, G. (1998) Differentiation of human NK cells into NK1 and NK2 subsets. J. Immunol. 161, 5821-5824.
166. Deniz, G., Akdis, M., Aktas, E., Blaser, K., and Akdis, C. A. (2002) Human NK1 and NK2 subsets determined by purification of IFN-gamma-secreting and IFN-gamma-nonsecreting NK cells. Eur. J. Immunol. 32, 879-884.
167. Chakir, H., Camilucci, A. A., Filion, L. G., and Webb, J. R. (2000) Differentiation of murine NK cells into distinct subsets based on variable expression of the IL-12R beta 2 subunit. J. Immunol. 165, 4985-4993.
168. Loza, M. J. and Perussia, B. (2001) Final steps of natural killer cell maturation: a model for type 1-type 2 differentiation? Nat. Immunol. 2, 917-924.
169. Cella, M., Fuchs, A., Vermi, W., Facchetti, F., Otero, K., Lennerz, J. K., Doherty, J. M., Mills, J. C., and Colonna, M. (2009) A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457, 722-725.
170. + lineage distinct from conventional natural killer cells. J. Exp. Med. 207, 281-290.
171. + cell subsets from Id2-dependent precursors. J. Exp. Med. 207, 273-280.
172. Hughes, T., Becknell, B., McClory, S., Briercheck, E., Freud, A. G., Zhang, X., Mao, H., Nuovo, G., Yu, J., and Caligiuri, M. A. (2009) Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood 113, 4008-4010.
173. + progenitors promoted by membrane-bound IL-15. PLoS One 3, e2241.
174. O'Leary, J. G., Goodarzi, M., Drayton, D. L., and von Andrian, U. H. (2006) T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat. Immunol. 7, 507-516.
175. Sun, J. C., Beilke, J. N., and Lanier, L. L. (2009) Adaptive immune features of natural killer cells. Nature 457, 557-561.
176. Cooper, M. A., Elliott, J. M., Keyel, P. A., Yang, L., Carrero, J. A., and Yokoyama, W. M. (2009) Cytokine-induced memory-like natural killer cells. Proc. Natl. Acad. Sci. USA 106, 1915-1919.
177. Hanna, J., Gonen-Gross, T., Fitchett, J., Rowe, T., Daniels, M., Arnon, T. I., Gazit, R., Joseph, A., Schjetne, K. W., Steinle, A., Porgador, A., Mevorach, D., Goldman-Wohl, D., Yagel, S., LaBarre, M. J., Buckner, J. H., and Mandelboim, O. (2004) Novel APC-like properties of human NK cells directly regulate T cell activation. J. Clin. Invest. 114, 1612-1623.
178. Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A. K., and Flavell, R. A. (2006) Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24, 99-146.
179. Bellone, G., Aste-Amezaga, M., Trinchieri, G., and Rodeck, U. (1995) Regulation of NK cell functions by TGF-beta 1. J. Immunol. 155, 1066-1073.
180. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 202, 1075-1085.
181. Ortaldo, J. R., Mason, A. T., O'shea, J. J., Smyth, M. J., Falk, L. A., Kennedy, I. C., Longo, D. L., and Ruscetti, F. W. (1991) Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J. Immunol. 146, 3791-3798.
182. Laouar, Y., Sutterwala, F. S., Gorelik, L., and Flavell, R. A. (2005) Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat. Immunol. 6, 600-607.
183. Rook, A. H., Kehrl, J. H., Wakefield, L. M., Roberts, A. B., Sporn, M. B., Burlington, D. B., Lane, H. C., and Fauci, A. S. (1986) Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 136, 3916-3920.
184. + regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA 102, 9253-9257.
185. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176, 1582-1587.
186. Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., and Moretta, A. (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. USA 100, 4120-4125.
187. Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., and Weller, M. (2004) RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64, 7596-7603.
188. Lee, J.-C., Lee, K.-M., Kim, D.-W., and Heo, D. S. (2004) Elevated TGF-{beta}1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172, 7335-7340.
189. Su, H. C., Leite-Morris, K. A., Braun, L., and Biron, C. A. (1991) A role for transforming growth factor-beta 1 in regulating natural killer cell and T lymphocyte proliferative responses during acute infection with lymphocytic choriomeningitis virus. J. Immunol. 147, 2717-2727.
190. + T cells, IL-2, and NK cell-derived TGF-beta: contrasting effects of anti-CD2 and anti-CD3. J. Immunol. 160, 2248-2254.
191. Wing, K. and Sakaguchi, S. (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11, 7-13.
192. Zwirner, N. W., Croci, D. O., Domaica, C. I., and Rabinovich, G. A. (2010) Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. Curr. Pharm. Des. 16, 255-267.
193. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M. L., Knutson, K. L., Chen, L., and Zou, W. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942-949.
194. Mailloux, A. W. and Young, M. R. (2009) NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J. Immunol. 182, 2753-2765.
195. Couper, K. N., Blount, D. G., and Riley, E. M. (2008) IL-10: the master regulator of immunity to infection. J. Immunol. 180, 5771-5777.
196. Mocellin, S., Panelli, M., Wang, E., Rossi, C. R., Pilati, P., Nitti, D., Lise, M., and Marincola, F. M. (2004) IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun. 5, 621-630.
197. Neyer, L. E., Grunig, G., Fort, M., Remington, J. S., Rennick, D., and Hunter, C. A. (1997) Role of interleukin-10 in regulation of T-cell-dependent and T-cell-independent mechanisms of resistance to Toxoplasma gondii. Infect. Immun. 65, 1675-1682.
198. +Ly49- liver NK cells in a functionally hyporesponsive state. J. Immunol. 184, 2693-2701.
199. Dougan, M. and Dranoff, G. (2009) Immune therapy for cancer. Annu. Rev. Immunol. 27, 83-117.
200. Vicari, A. P. and Caux, C. (2002) Chemokines in cancer. Cytokine Growth Factor Rev. 13, 143-154.